Traduction de «acquisition of privately-held alacer corp » (Néerlandais → Français) :

Maker of Emergen-C®, #1 U.S. Vitamin C Brand, Expands Pfizer’s Vitamin and Dietary Supplement Business NEW YORK, N.Y., February 27 - Pfizer Inc (NYSE:PFE) today announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.
- - - Maker of Emergen-C®, #1 U.S. Vitamin C Brand, Expands Pfizer’s Vitamin and Dietary Supplement Business NEW YORK, N.Y., February 27 - Pfizer Inc (NYSE:PFE) today announced the acquisition of privately-held Alacer Corp., the maker and distributor of Emergen-C products, the largest selling branded Vitamin C line in the United States.

Pharmaceuticals – Corthera On February 3, Novartis completed the acquisition of the privately held US based Corthera Inc., gaining worldwide rights to Relaxin for the treatment of acute decompensated heart failure and assumed full responsibility for development and commercialization for a total purchase consideration of USD 327 million.
Pharmaceuticals – Corthera Le 3 février, Novartis a achevé l’acquisition de Corthera Inc., une entreprise américaine non cotée, pour un prix total d’USD 327 millions.

Sandoz – Oriel Therapeutics On June 1, Sandoz completed the acquisition of the privately held US based Oriel Therapeutics Inc., to broaden its portfolio of projects in the field of respiratory drugs for a total purchase consideration of USD 332 million.
Sandoz – Oriel Therapeutics Le 1 er juin, Sandoz a terminé l’acquisition d’Oriel Therapeutics Inc., une entreprise américaine non cotée, afin d’élargir son portefeuille de projets dans le domaine des médicaments respiratoires. Le prix d’achat s’élève à USD 332 millions.

On June 1, Sandoz completed the acquisition of Oriel Therapeutics, a privately held US pharmaceuticals company.
Le 1 er juin, Sandoz a achevé l’acquisition d’Oriel Therapeutics, une société américaine non cotée.

Sandoz – Oriel Therapeutics On June 1, Sandoz completed the acquisition of the privately held US based Oriel Therapeutics Inc., to broaden its portfolio of projects in the field of respiratory drugs for a total purchase consideration of USD 329 million.
Sandoz – Oriel Therapeutics Le 1 er juin, Sandoz a terminé l’acquisition d’Oriel Therapeutics Inc., une entreprise américaine non cotée, afin d’élargir son portefeuille de projets dans le domaine des médicaments respiratoires. Le prix d’achat s’élève à USD 329 millions.